Pfizer to spend $11.6B on migraine treatment maker Biohaven

Published: Updated:
Read Mode
100% Font Size
1 min read

Pfizer is spending more than $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own.

The New York drugmaker said Tuesday it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development.

For the latest headlines, follow our Google News channel online or via the app.

The price represents a 33 percent premium over Biohaven’s 90-day weighted average trading price of $111.70 for Biohaven Pharmaceutical Holding Co. Ltd., which is based in New Haven, Connecticut.

Shares of Biohaven, which had tumble below $100 in recent weeks, soared 72 percent before the opening bell to about $72. Pfizer’s stock slipped.

Pfizer Inc. has been flush with cash in recent quarters, thanks in part to sales of its COVID-19 vaccine Comirnaty and now its pill treatment for the virus, Paxlovid.

Read more:

Thailand targets homegrown mRNA COVID-19 vaccine rollout by end-2022

EU watchdog assesses Moderna COVID-19 vaccine for under-fives

Pfizer to buy lung-focused biotech developer ReViral for as much as $525 mln

Top Content Trending